Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-js']jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US

被引：7

作者：

Lodise, Thomas ^{[1
]}

Guo, Amy ^{[2
]}

Yang, Min ^{[3
]}

Cook, Erin E. ^{[3
]}

Song, Wei ^{[3
]}

Yang, Danni ^{[3
]}

Wang, Qingyuan ^{[4
]}

Zhao, Angela ^{[3
]}

Bochan, Markian ^{[5
]}

机构：

[1] Albany Coll Pharm & Hlth Sci, Albany, NY USA

[2] Ferring Pharmaceut Inc, Med Affairs, 100 Interpace Pkwy, Parsippany, NJ 07054 USA

[3] Anal Grp, Boston, MA USA

[4] Anal Grp, London, England

[5] Outpatient Integrated Strategies, Carmel, IN USA

来源：

ADVANCES IN THERAPY | 2023年 / 40卷 / 06期

关键词：

Recurrent Clostridioides difficile infection; FMBL; Budget impact; Economic modeling; DIVERTING LOOP ILEOSTOMY; MEDICARE; COSTS;

D O I：

10.1007/s12325-023-02506-0

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

IntroductionPatients with Clostridioides difficile infection (CDI) often experience recurrences (rCDI), which are associated with high morbidity, mortality, and healthcare expenditures. REBYOTA (TM) (fecal microbiota, live-jslm [FMBL]) is a microbiota-based live biotherapeutic approved for the prevention of rCDI following antibiotic treatment for rCDI. We quantified the budget impact of FMBL during the first 3 years following introduction from a third-party US payer perspective.MethodsA decision-tree model was used to estimate the budget impact of one-course FMBL by comparing costs under the scenario with FMBL to the scenario without FMBL (standard of care) in patients with one or more (>= 1) recurrences after a primary episode of CDI and had completed >= 1 round of antibiotic treatments. Drug costs, rCDI-related medical costs, and budget impact over 1-3 years were estimated in 2022 US dollars. One-way sensitivity analyses were performed.ResultsFor an insurance plan with a population size of 1,000,000, 468 patients per year were estimated to have >= 1 rCDI. The budget impact of one-course FMBL at $9000/course was cost-saving at an >> average of -$0.0039 on a per-member-per-month (PMPM) basis, an average of -$8.30 on a per-treated-member-per-month (PTMPM) basis, and a total of -$139,865 on a plan level assuming 5%, 15%, and 20% of patients receive FMBL over 1-3 years, respectively. The scenario with FMBL entry was associated with higher drug costs (difference at $0.0474 PMPM; $101.26 PTMPM; $1,706,445 total plan) and lower rCDI-related medical costs (difference at -$0.0513 PMPM; -$109.56 PTMPM; -$1,846,309 total plan). The budget impact of FMBL in patients at first rCDI was cost-saving at -$0.0139 PMPM, -$84.78 PTMPM, corresponding to an annual savings of $500,022.ConclusionsFMBL has a cost-saving budget impact for a US payer, with higher initial drug costs being offset by savings in rCDI-related medical costs. Greater cost saving was found in patients at first recurrence.

引用

页码：2801 / 2819

页数：19

共 36 条

[11] Clostridium difficile in Food and Domestic Animals: A New Foodborne Pathogen? [J].